Heart experts say Arcoxia too risky for approval and use

Share this article:
A pair of prominent heart experts said in a published report Thursday that studies of Merck’s COX-2 selective inhibitor Arcoxia revealed risks that make it unacceptable for approval in the US and that the drug poses unacceptable dangers to patients in countries where it is already sold. The concerns were expressed in an interview with Reuters by Dr. Steven Nissen, head of cardiology at the Cleveland Clinic and Dr. Curt Furberg, a professor of public health at Wake Forest University who is a member of the Drug Safety and Risk Management Advisory Committee of the FDA. Nissen and Furberg said patients taking Arcoxia in a large international trial had a higher incidence of edema, elevated blood pressure and congestive heart failure than patients taking the standard treatment, diclofenac. Nissen said, “This is a genie I don’t want to see let out of the bottle,” predicting the FDA will refuse to approve Arcoxia. Furberg added that “all versions of Arcoxia should be taken off the market now,” referring to the 63 nations where Arcoxia is currently approved for use. Merck spokesman Chris Loder told Reuters he disagreed with Nissen’s and Furberg’s assessment of Arcoxia. “The product has been evaluated and re-evaluated by regulators in 63 countries, including the European Union,” Loder said. He added that regulators continue to believe the drug’s benefits outweigh its risks. Merck is currently awaiting FDA approval of Arcoxia, which works through the same mechanism as Vioxx. Arcoxia had global sales of $265 million last year.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...